PAVmed Inc. (PAVM)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 6 | 8 | 996 | 979 |
| Sales and marketing | 220 | 247 | 2,920 | 4,242 |
| Research and development | 790 | 787 | 1,542 | 1,641 |
| General and administrative | 3,670 | 4,384 | 6,649 | 7,009 |
| Cost of revenue | 41 | 36 | 1,381 | 1,666 |
| Amortization of acquired intangible assets | - | - | 82 | 105 |
| Total operating expenses | 4,721 | 5,454 | 12,574 | 14,663 |
| Operating loss | -4,715 | -5,446 | -11,578 | -13,684 |
| Gain on deconsolidation | - | - | 72,287 | - |
| Interest income | 8 | 8 | 70 | 110 |
| Interest expense | 4 | 4 | 12 | 11 |
| Debt extinguishments loss - senior secured convertible notes | - | -58 | -1,403 | -763 |
| Change in fair value - equity method investment | -10,643 | 21,004 | 407 | - |
| Management fee income | 3,150 | 3,150 | 700 | - |
| Grant income | 80 | 18 | - | - |
| Debt modification expense | - | - | - | - |
| Change in fair value - senior secured convertible notes | 200 | 49 | -240 | 566 |
| Other income (expense), net | -7,609 | 24,069 | 72,289 | -1,230 |
| Income (loss) before provision for income tax | -12,324 | 18,623 | 60,711 | -14,914 |
| Provision for income taxes | - | - | - | - |
| Net income (loss) before noncontrolling interests | -12,324 | 18,623 | 60,711 | -14,914 |
| Net loss attributable to the noncontrolling interests | -403 | -345 | -3,688 | -4,087 |
| Net income (loss) attributable to pavmed inc | -11,921 | 18,968 | 64,399 | -10,827 |
| Less series c convertible preferred stock dividends earned | 481 | 398 | - | - |
| Less deemed dividend on subsidiary preferred stock attributable to the noncontrolling interests | - | - | - | - |
| Less deemed dividend on series c convertible preferred stock | -818 | -789 | - | - |
| Less series b convertible preferred stock dividends earned | 88 | 86 | 83 | 81 |
| Net income (loss) attributable to pavmed inc. common stockholders | -13,308 | 17,695 | 64,316 | -10,908 |
| Net income (loss) per share attributable to pavmed inc. common stockholders basic | -0.74 | 1.28 | 6.43 | - |
| Net income (loss) per share attributable to pavmed inc. common stockholders diluted | -0.74 | 0.34 | 1.44 | -1.19 |
| Weighted average common shares outstanding, basic | 18,084,653 | 13,876,165 | 10,005,379 | 9,152,819 |
| Weighted average common shares outstanding, diluted | 18,084,653 | 52,496,401 | 44,475,638 | 9,152,819 |